Aseptic loosening of BonelocR cemented hip prostheses

Randomized controlled trial comparing traditional versus enhanced-fixation designs of a novel cemented total knee arthroplasty tibial component

Aims

A novel enhanced cement fixation (EF) tibial implant with deeper cement pockets and a more roughened bonding surface was released to market for an existing total knee arthroplasty (TKA) system.This randomized controlled trial assessed fixation of the both the EF (ATTUNE S+) and standard (Std; ATTUNE S) using radiostereometric analysis.

Methods

Overall, 50 subjects were randomized (21 EF-TKA and 23 Std-TKA in the final analysis), and had follow-up visits at six weeks, and six, 12, and 24 months to assess migration of the tibial component. Low viscosity bone cement with tobramycin was used in a standardized fashion for all subjects. Patient-reported outcome measure data was captured at preoperative and all postoperative visits.

Results

The patient cohort mean age was 66 years (SD seven years), 59% were female, and the mean BMI was 32 kg/m2 (SD 6 kg/m2). Mean two-year subsidence of the EF-TKA was 0.056 mm (95% confidence interval (CI) 0.025 to 0.086) versus 0.006 mm (95% CI -0.029 to 0.040) for the Std-TKA, and the two-year maximum total point motion (MTPM) was 0.285 mm (95% upper confidence limit (UCL) ≤ 0.363) versus 0.346 mm (95% UCL ≤ 0.432), respectively, for a mean difference of -0.061 mm (95% CI -0.196 to 0.074). Inducible displacement also did not differ between groups. The MTPMs between 12 and 24 months for each group was below the published threshold of 0.2 mm for predicting early aseptic loosening (p < 0.001 and p = 0.001, respectively).

Conclusion

Both the enhanced fixation and the standard tibial implant design showed fixation with a predicted low risk of long-term aseptic loosening.

Effect of long-term physiological activity on the long-term stem stability of cemented hip arthroplasty: in vitro comparison of three commercial bone cements

Long-term endurance of the cement mantle is fundamental for the survival of cemented hip prostheses. Current protocols to characterize bone cements are unsuitable to predict the actual clinical outcome. The aim of this study was to assess if it is possible to rank cement types having diverse clinical outcome by using a simplified in vitro physiological test. Composite femurs were implanted with identical stems (Lubinus-SPII), using different commercial cement types: CMW1 to represent cement with poor clinical outcome; Simplex-P and Cemex-RX to represent cements with a positive clinical outcome. Implanted femurs were subjected to a validated protocol that simulated a demanding but physiological loading spectrum. Inducible micromotions and permanent migrations were recorded throughout the test. After test completion, the cement mantles were sectioned and inspected with dye penetrants to quantify the fatigue-induced cracks. Micromotions did not differ significantly between cement types (possibly because a successful prosthesis was chosen that is very stable in the host bone). Significant differences were observed in terms of cement cracks: CMW1 induced significantly more numerous and larger cracks than Simplex-P and Cemex-RX; no difference was observed between Simplex-P and Cemex-RX. This indicates that this protocol: (a) can discriminate between ‘good’ and ‘bad’ cements and (b) yields consistent results when comparable cements are tested. The proposed protocol overcomes the limitations of existing standardized material tests for bone cements. New cements can be assessed in comparison with other cements with known (positive/negative) clinical outcome, tested with the same protocol.

Total hip arthroplasty with Boneloc cement: Unsatisfactory results in 163 hips after 9 to 11 years

Boneloc bone cement was introduced in the Netherlands in 1992. Inferior short-term results were reported which led to the withdrawal of Boneloc from clinical use in 1995. However, little is known about the long-term outcome of hip arthroplasties with Boneloc. Between April 1992 and August 1994, Boneloc was used in 163 Mallory-Head primary total hip arthroplasties in 163 patients. Follow-up analysis was performed in 2003. To date, 27 hips (17%) have been revised for aseptic loosening of the femoral component. Median time to revision was 5.5 years. Survival analysis based on revision for aseptic loosening showed 77% cumulative survival at 11 years. With revision for aseptic loosening and/or definite radiological loosening according to Harris as endpoint, cumulative survival was 59% at 11 years. In 27 of 43 patients with definite radiological loosening, a cement fracture was seen at a median of 2.9 years. These results show failure of Boneloc cemented total hip arthroplasties occurring even during the later follow-up. Continuing periodic clinical and radiological examination is recommended. (Hip International 2004; 14: 229-32).

Boneloc bone-cement: experience in hip arthroplasty during a 3-year period

Polymethyl methacrylate (PMMA) bone-cement was introduced in the 1960s for fixation of total hip arthroplasty replacement components. Long-term results of cement fixation for hip and knee arthroplasty have been extremely good. Although the use of PMMA bone-cement has enabled long-term survival of joint arthroplasty implants, there has been concern about aseptic loosening. This concern led to the introduction of Boneloc bone-cement (Biomet, Warsaw, IN) in the early 1990s. It was hoped that with the improved physical and chemical characteristics of Boneloc, there would be less aseptic loosening in the long-term. A clinical trial was conducted to evaluate Boneloc bone-cement in cementing the femoral component of the Bimetric total hip arthroplasty prosthesis in 33 hips in 32 patients. On follow-up, 7 stems (24%) developed definite loosening, and 3 stems (10%) were possibly loose. Of the 7 definite loose stems, 5 (17%) were revised because of increasing pain or progressive loosening. Despite the biologic advantages of Boneloc, this study suggests that the chemicals substituted in Boneloc bone-cement led to an alteration in its mechanical properties. These properties proved to be inferior to conventional PMMA bone-cement. There is possible time-dependent deterioration of mechanical properties leading to early aseptic loosening. The conventional PMMA bone-cement has stood the test of time. Research and experimental studies should continue to improve the mechanical properties of Boneloc before further human trials.

Bone loss around failed femoral implant measured by dual-energy X-ray absorptiometry

Periprosthetic bone mineral density (BMD) and its changes after primary total hip arthroplasty (THA) have been studied extensively, but quantitative data on BMD around loosened prostheses are still lacking. In this study, using dual-energy X-ray absorptiometry (DXA), we determined periprosthetic BMD in 19 patients with failed primary THA. There was a decrease in BMD (8. 8%-25.5%) in every Gruen zone as compared with the patient's non-operated (control) side. Although the bone loss was most significant in the proximal femur, as in primary THA, the pattern of bone loss around the failed THA differred from the typical remodeling seen after successful THA. We suggest that quantitation of bone mass around the failed femoral stem is possible. Remarkable generalized bone loss around the stem is associated with a loosened prosthesis.

No biological advantage with a low temperature curing versus a conventional bone cement: an experimental, mechanical and histomorphometrical study in the rabbit tibia

Both tibial marrow cavities of 12 rabbits were evacuated and filled with curing bone cement. In one of the tibias conventional curing bone cement (Simplex P) was injected, while the other tibia of the same animal was filled with a low temperature curing bone cement (Boneloc). Three titanium implants were inserted along the proximal metaphysis of each tibia. Eight weeks after insertion the most distal implant in each tibia was removed while recording the removal torque. The implant was then once again screwed home into its bone bed. The animals were sacrificed 16 weeks after implant insertion. The previously removed implant and another implant in each tibia were then both removed while recording the removal torque. The third implant in each tibia was cut out en bloc with surrounding tissue and processed for ground section. We found no statistical differences in the mechanical or the histomorphometric evaluation of implant integration between the two cements, indicating that the low temperature curing bone cement does not result in a significantly different bone response from that of a conventional acrylic cement.